用于治疗局灶性癫痫发作的抗癫痫药物的严重不良反应。

IF 3 3区 医学 Q2 PHARMACOLOGY & PHARMACY Expert Opinion on Drug Safety Pub Date : 2025-02-01 Epub Date: 2024-12-25 DOI:10.1080/14740338.2024.2446416
Miloš Milosavljević, Slobodan M Janković
{"title":"用于治疗局灶性癫痫发作的抗癫痫药物的严重不良反应。","authors":"Miloš Milosavljević, Slobodan M Janković","doi":"10.1080/14740338.2024.2446416","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The third-generation antiseizure medications used for the treatment of focal seizures, lacosamide, eslicarbazepine acetate, perampanel, brivaracetam, and cenobamate, may elicit serious adverse reactions which could be preventable if a prescriber is acquainted with the risk factors.</p><p><strong>Areas covered: </strong>The literature search was conducted in MEDLINE, SCOPUS, and EBSCO databases, without time and language restrictions. Only clinical studies, observational human studies, case reports, and case series that reported serious adverse drug reactions and risk factors were considered.</p><p><strong>Expert opinion: </strong>In order to prevent psychiatric side effects, the use of these drugs in patients with psychiatric disorders in the past should be avoided, or intensive monitoring of patients should be undertaken in order to detect psychosis or depression as early as possible. When prescribed eslicarbazepine and perampanel, serum sodium and ammonia levels should be periodically monitored. Lacosamide is associated with rhythm and conduction disturbances in the myocardium, so caution and ECG monitoring are required in people with cardiac diseases. Eslicarbazepine, cenobamate, and lacosamide can cause Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome and other allergic manifestations, so they should be used with caution in people with allergies in medical history.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"129-143"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serious adverse effects of selected antiseizure medications used for treatment of focal onset seizures.\",\"authors\":\"Miloš Milosavljević, Slobodan M Janković\",\"doi\":\"10.1080/14740338.2024.2446416\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The third-generation antiseizure medications used for the treatment of focal seizures, lacosamide, eslicarbazepine acetate, perampanel, brivaracetam, and cenobamate, may elicit serious adverse reactions which could be preventable if a prescriber is acquainted with the risk factors.</p><p><strong>Areas covered: </strong>The literature search was conducted in MEDLINE, SCOPUS, and EBSCO databases, without time and language restrictions. Only clinical studies, observational human studies, case reports, and case series that reported serious adverse drug reactions and risk factors were considered.</p><p><strong>Expert opinion: </strong>In order to prevent psychiatric side effects, the use of these drugs in patients with psychiatric disorders in the past should be avoided, or intensive monitoring of patients should be undertaken in order to detect psychosis or depression as early as possible. When prescribed eslicarbazepine and perampanel, serum sodium and ammonia levels should be periodically monitored. Lacosamide is associated with rhythm and conduction disturbances in the myocardium, so caution and ECG monitoring are required in people with cardiac diseases. Eslicarbazepine, cenobamate, and lacosamide can cause Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome and other allergic manifestations, so they should be used with caution in people with allergies in medical history.</p>\",\"PeriodicalId\":12232,\"journal\":{\"name\":\"Expert Opinion on Drug Safety\",\"volume\":\" \",\"pages\":\"129-143\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14740338.2024.2446416\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2446416","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

简介:用于治疗局灶性癫痫发作的第三代抗癫痫药物拉科沙胺、醋酸埃斯卡巴西平、perampanel、布瓦西坦和cenobamate可能引起严重的不良反应,如果处方者熟悉危险因素,这些不良反应是可以预防的。文献检索在MEDLINE、SCOPUS和EBSCO数据库中进行,没有时间和语言限制。仅考虑报告严重药物不良反应和危险因素的临床研究、观察性人体研究、病例报告和病例系列。专家意见:为防止精神方面的副作用,应避免既往有精神障碍的患者使用这些药物,或对患者进行严密监测,以便尽早发现精神病或抑郁症。当处方埃斯卡巴西平和perampanel时,应定期监测血清钠和氨水平。拉科沙胺与心肌节律和传导障碍有关,因此心脏病患者需要谨慎使用并进行心电图监测。埃斯卡巴西平、辛奥巴酸、拉科沙胺可引起药物性皮疹伴嗜酸性粒细胞增多及全身症状(DRESS)综合征等过敏表现,故既往有过敏史者慎用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Serious adverse effects of selected antiseizure medications used for treatment of focal onset seizures.

Introduction: The third-generation antiseizure medications used for the treatment of focal seizures, lacosamide, eslicarbazepine acetate, perampanel, brivaracetam, and cenobamate, may elicit serious adverse reactions which could be preventable if a prescriber is acquainted with the risk factors.

Areas covered: The literature search was conducted in MEDLINE, SCOPUS, and EBSCO databases, without time and language restrictions. Only clinical studies, observational human studies, case reports, and case series that reported serious adverse drug reactions and risk factors were considered.

Expert opinion: In order to prevent psychiatric side effects, the use of these drugs in patients with psychiatric disorders in the past should be avoided, or intensive monitoring of patients should be undertaken in order to detect psychosis or depression as early as possible. When prescribed eslicarbazepine and perampanel, serum sodium and ammonia levels should be periodically monitored. Lacosamide is associated with rhythm and conduction disturbances in the myocardium, so caution and ECG monitoring are required in people with cardiac diseases. Eslicarbazepine, cenobamate, and lacosamide can cause Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome and other allergic manifestations, so they should be used with caution in people with allergies in medical history.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
3.20%
发文量
97
审稿时长
6-12 weeks
期刊介绍: Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
期刊最新文献
Drug-induced hyperacusis: a disproportionality analysis of the FAERS database. Drug-associated pancreatic cancer: insights from real-world pharmacovigilance and network pharmacology. Post-marketing safety monitoring of Tirzepatide: a pharmacovigilance study based on the FAERS database. Update of safety profile of levonorgestrel: a disproportionality analysis based on FAERS from 2004 to 2023. Incidence and risk of drug-induced interstitial lung disease associated with anti-neoplastic drugs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1